Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
Gladstone et al.
Stroke 2009;40:235-240.
ABSTRACT
| FULL TEXT
A Novel Endovascular Device for Emboli Rerouting: Part I: Evaluation in a Swine Model
Grad et al.
Stroke 2008;39:2860-2866.
ABSTRACT
| FULL TEXT
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
Garcia et al.
The Annals of Pharmacotherapy 2008;42:979-988.
ABSTRACT
| FULL TEXT
A Randomized, Placebo-Controlled Trial of Citalopram for the Prevention of Major Depression During Treatment for Head and Neck Cancer
Lydiatt et al.
Arch Otolaryngol Head Neck Surg 2008;134:528-535.
ABSTRACT
| FULL TEXT
Percutaneous left atrial appendage obliteration.
Hara et al.
J Am Coll Cardiol Img 2008;1:92-93.
FULL TEXT
Anticoagulation for elderly patients with atrial fibrillation: not to be neglected
Taggar and Lip
Europace 2008;10:1-2.
FULL TEXT
Barriers to Anticoagulation in Patients With Atrial Fibrillation: Changing Physician-Related Factors
Lane and Lip
Stroke 2008;39:7-9.
FULL TEXT
Quality of Clinical Documentation and Anticoagulation Control in Patients With Chronic Nonvalvular Atrial Fibrillation in Routine Medical Care
Ansell et al.
American Journal of Medical Quality 2007;22:327-333.
ABSTRACT
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Hirsh et al.
Circulation 2007;116:552-560.
FULL TEXT
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
Connolly et al.
Circulation 2007;116:449-455.
FULL TEXT
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Hylek et al.
Circulation 2007;115:2689-2696.
ABSTRACT
| FULL TEXT
Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation
Sick et al.
J Am Coll Cardiol 2007;49:1490-1495.
ABSTRACT
| FULL TEXT
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Akins et al.
Stroke 2007;38:874-880.
ABSTRACT
| FULL TEXT
Serum lipid profile on admission for ischemic stroke: Failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines
Smith et al.
Neurology 2007;68:660-665.
ABSTRACT
| FULL TEXT
Reduced Poststroke Mortality in Patients With Stroke and Atrial Fibrillation Treated With Anticoagulants: Results From a Danish Quality-Control Registry of 22 179 Patients With Ischemic Stroke
Andersen and Olsen
Stroke 2007;38:259-263.
ABSTRACT
| FULL TEXT
Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.
Kakar et al.
Chest 2006;130:1296-1299.
FULL TEXT
Eligibility for Anticoagulation in Elderly Patients With Atrial Fibrillation
Ono et al.
Stroke 2006;37:2205-2205.
FULL TEXT
Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care
DeWilde et al.
Heart 2006;92:1064-1070.
ABSTRACT
| FULL TEXT
Atrial Fibrillation and Stroke in the General Medicare Population: A 10-Year Perspective (1992 to 2002)
Lakshminarayan et al.
Stroke 2006;37:1969-1974.
ABSTRACT
| FULL TEXT
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Somerfield et al.
Stroke 2006;37:1217-1220.
ABSTRACT
| FULL TEXT
Statin treatment and adherence to national cholesterol guidelines after ischemic stroke
Ovbiagele et al.
Neurology 2006;66:1164-1170.
ABSTRACT
| FULL TEXT
Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation
Hylek et al.
Stroke 2006;37:1075-1080.
ABSTRACT
| FULL TEXT
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis
Choudhry et al.
BMJ 2006;332:141-145.
ABSTRACT
| FULL TEXT
Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy
McGriff-Lee et al.
The Annals of Pharmacotherapy 2005;39:1996-2002.
ABSTRACT
| FULL TEXT
Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers
Capucci et al.
J Am Coll Cardiol 2005;46:1913-1920.
ABSTRACT
| FULL TEXT
Impact of Age, CYP2C9 Genotype and Concomitant Medication on the Rate of Rise for Prothrombin Time During the First 30 Days of Warfarin Therapy
Wilke et al.
Clin Med Res 2005;3:207-213.
ABSTRACT
| FULL TEXT
Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial
McAlister et al.
CMAJ 2005;173:496-501.
ABSTRACT
| FULL TEXT
Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy?
Wani et al.
BMJ 2005;331:439-442.
FULL TEXT
Uncertain times for oral anticoagulation therapy
Nutescu et al.
Am J Health Syst Pharm 2005;62:1449-1449.
FULL TEXT
Antithrombotic Therapy Practices in US Hospitals in an Era of Practice Guidelines
Tapson et al.
Arch Intern Med 2005;165:1458-1464.
ABSTRACT
| FULL TEXT
Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial Fibrillation: Results From the International Multi-Center Feasibility Trials
Ostermayer et al.
J Am Coll Cardiol 2005;46:9-14.
ABSTRACT
| FULL TEXT
Differences in quality of care among patients hospitalized with atrial fibrillation as primary or secondary cause for admission
Lim et al.
Int J Qual Health Care 2005;17:255-258.
ABSTRACT
| FULL TEXT
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation
Katira et al.
Postgrad. Med. J. 2005;81:370-375.
ABSTRACT
| FULL TEXT
Letter Regarding Article by Masoudi et al, "National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction" * Response
Sabatini et al.
Circulation 2005;111:e276-e277.
FULL TEXT
Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation
Schulman and Beyth
Eur Heart J Suppl 2005;7:C34-C40.
ABSTRACT
| FULL TEXT
Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
Miller et al.
Eur Heart J Suppl 2005;7:C41-C54.
ABSTRACT
| FULL TEXT
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Randomized Trial
SPORTIF Executive Steering Committee for the SPORT
JAMA 2005;293:690-698.
ABSTRACT
| FULL TEXT
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
O'Brien and Gage
JAMA 2005;293:699-706.
ABSTRACT
| FULL TEXT
Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril
Kim and Arora
J CARDIOVASC PHARMACOL THER 2005;10:11-21.
ABSTRACT
Anticoagulation in atrial fibrillation and flutter
Scholten et al.
Europace 2005;7:492-499.
ABSTRACT
| FULL TEXT
Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation
Fang et al.
ANN INTERN MED 2004;141:745-752.
ABSTRACT
| FULL TEXT
A Community-Based Educational Intervention to Improve Antithrombotic Drug Use in Atrial Fibrillation
Jackson et al.
The Annals of Pharmacotherapy 2004;38:1794-1799.
ABSTRACT
| FULL TEXT
PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events
Ovbiagele et al.
Neurology 2004;63:1217-1222.
ABSTRACT
| FULL TEXT
Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry
Steger et al.
Eur Heart J 2004;25:1734-1740.
ABSTRACT
| FULL TEXT
Presidential Reflections on the 25th Anniversary of the Society for Medical Decision Making
Elstein et al.
Med Decis Making 2004;24:408-420.
The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation
Ezekowitz and Falk
Mayo Clin Proc. 2004;79:904-913.
ABSTRACT
How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study
Lipman et al.
Fam Pract 2004;21:290-298.
ABSTRACT
| FULL TEXT
Elimination of the Left Atrial Appendage To Prevent Stroke or Embolism?: Anatomic, Physiologic, and Pathophysiologic Considerations
Stollberger et al.
Chest 2003;124:2356-2362.
ABSTRACT
| FULL TEXT
Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation
Johnston et al.
Arch Intern Med 2003;163:1705-1710.
ABSTRACT
| FULL TEXT
Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
Petersen et al.
J Am Coll Cardiol 2003;41:1445-1451.
ABSTRACT
| FULL TEXT
Rhythm or Rate Control in Atrial Fibrillation: Insights from the Randomized Controlled Trials
Gronefeld and Hohnloser
J CARDIOVASC PHARMACOL THER 2003;8:S39-S44.
ABSTRACT
Is treatment of atrial fibrillation in primary care based on thromboembolic risk assessment?
Rutten et al.
Fam Pract 2003;20:16-21.
ABSTRACT
| FULL TEXT
Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation Therapy: The West Birmingham Atrial Fibrillation Project * Editorial Comment: The West Birmingham Atrial Fibrillation Project
Lip et al.
Stroke 2002;33:238-242.
ABSTRACT
| FULL TEXT
Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation
Garcia et al.
Stroke 2002;33:322-324.
FULL TEXT
Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients With Atrial Fibrillation?
Evans et al.
Stroke 2001;32:2828-2832.
ABSTRACT
| FULL TEXT
Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation
Wehinger et al.
Stroke 2001;32:2246-2252.
ABSTRACT
| FULL TEXT
Keynote address
Fieschi and Falcou
Neurology 2001;57:S82-86.
ABSTRACT
| FULL TEXT
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation
Bungard et al.
CMAJ 2001;165:301-302.
FULL TEXT
Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting
Yood et al.
Arch Intern Med 2001;161:1322-1327.
ABSTRACT
| FULL TEXT
Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe : Data From a Multicenter Multinational Hospital-Based Registry (The European Community Stroke Project)
Lamassa et al.
Stroke 2001;32:392-398.
ABSTRACT
| FULL TEXT
The Use of Practitioner Education and a Warfarin Monitoring Service to Improve Anticoagulation Practices
Gaughan
Arch Intern Med 2000;160:2401-2402.
FULL TEXT
Geriatric Assessment and Anticoagulation in Elderly Patients With Chronic Atrial Fibrillation
Bellelli et al.
Arch Intern Med 2000;160:2402-2403.
FULL TEXT
Warfarin Therapy for Atrial Fibrillation: The Patient's Preference Is Important
Fahey et al.
Arch Intern Med 2000;160:2403-2403.
FULL TEXT
The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis Commentary: patients, preferences, and evidence
Protheroe et al.
BMJ 2000;320:1380-1384.
ABSTRACT
| FULL TEXT
Quality of Anticoagulation Management Among Patients With Atrial Fibrillation: Results of a Review of Medical Records From 2 Communities
Samsa et al.
Arch Intern Med 2000;160:967-973.
ABSTRACT
| FULL TEXT
Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation
Carlsson et al.
Europace 2000;2:115-118.
ABSTRACT
